CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 219 enrolled
Drug / intervention
14 day PBMT group +2 moredrug
Likely dose
14 day PBMT group 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02349685
NCT02349685N/ACompleted

The Efficacy of the Culture Based Tailored Therapy for Helicobacter Pylori Eradication Comparing With the Traditional 2nd Line Rescue Therapy in Korean

Seoul National University Bundang Hospital·interventional·Posted Jan 29, 2015·Updated Oct 4, 2016

In Brief

A clinical study evaluating H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, and 1 other intervention for Helicobacter Infection. Completed, enrolled 219 participants.

Detailed Summary

As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens, and the investigators analyzed the prevalence of the antibiotic resistance after 1st eradication of H. pylori in the tailored therapy group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 29, 2015
Enrollment StartJan 1, 2010
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.4 years ago

Interventions

H. pylori culture and antimicrobial susceptibility testprocedure

Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).

14 day PBMT groupdrug

Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]

14 day MEA groupdrug

Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)